Additionally, GO-Y030 treatment resulted in a significantly reduced Foxp3+ Tregs population in tumor-infiltrating lymphocytes compared with that from DMSO treatment (Figures 6C, D). The gene discussed is FOXP3; the disease is neoplasm.